At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 300 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Patients With Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 8)
In Brief
A Phase 3 clinical trial evaluating Placebo, Dulaglutide, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 300 participants across 31 sites in 8 countries.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of once-weekly dulaglutide compared to placebo in participants with type 2 diabetes who have inadequate glycemic control with sulfonylurea monotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesArgentina, Austria, Croatia, Mexico, Romania, Slovenia, South Africa, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2013
First PostedJan 2013
Primary CompletionDec 2014
TodayJul 2026
First PostedJan 16, 2013
Enrollment StartJan 1, 2013
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 13.5 years ago
Interventions
Placebodrug
Administered SQ
Dulaglutidedrug
Administered SQ
Glimepiridedrug
Administered PO